

SENATE

'21 MAY -4 P3:58

S. B. No. 2155

RECEIVED

INTRODUCED BY SENATOR CHRISTOPHER LAWRENCE "BONG" T. GO

**AN ACT
PROVIDING FOR THE FRAMEWORK FOR THE ESTABLISHMENT AND
OPERATION OF VIROLOGY LABORATORIES IN THE PHILIPPINES,
CREATING FOR THE PURPOSE THE VIROLOGY SCIENCE AND TECHNOLOGY
INSTITUTE OF THE PHILIPPINES (VIP), APPROPRIATING FUNDS
THEREFOR AND FOR OTHER PURPOSES**

EXPLANATORY NOTE

In the last fifty years, ten major virus outbreaks have been recorded with the recent outbreak of the coronavirus (SARS-CoV-2) infecting 146 million people globally as of April 25, 2021. The Philippines had its first million cases recorded on April 26, 2021.

These outbreaks could have been prevented or handled more efficiently in the presence of a national virology laboratory that will conduct surveillance, diagnosis and monitoring of viral diseases in humans, plants and animals. Understanding the genetic changes in viral genome is a prerequisite for a strong public health response to emerging, re-emerging and existing viral diseases.

As the government strives to address the situation and save more lives, we must learn from these experiences, identify gaps in government response mechanisms, and be more proactive in preparing for other similar crises in the future.

The government, led by the Department of Science and Technology and the

Department of Trade and Industry, has ongoing efforts, in coordination with the private sector, to set the foundation of being 'vaccine self-reliant' in the years to come. Preparations and initiatives to locally manufacture and eventually develop our own vaccines against COVID-19 and other diseases must start now.

In the long term, investing heavily on health research initiatives should be pursued. President Rodrigo Duterte has called the establishment of a virology institute that will capacitate the country to conduct scientific research initiatives on preventing and treating various viruses and diseases.

This bill calls for the establishment of an Institute that shall be the principal laboratory of the country in providing quality virology laboratory investigations, researches and technical coordination of the entire network of the virology laboratories in the Philippines.

In view of the foregoing, approval of this bill is earnestly sought.




SENATOR CHRISTOPHER LAWRENCE "BONG" T. GO

'21 MAY -4 P3 :58

SENATE
S. B. No. 2155

RECEIVED BY



INTRODUCED BY SENATOR CHRISTOPHER LAWRENCE "BONG" T. GO

AN ACT
PROVIDING FOR THE FRAMEWORK FOR THE ESTABLISHMENT AND
OPERATION OF VIROLOGY LABORATORIES IN THE PHILIPPINES, CREATING
FOR THE PURPOSE THE VIROLOGY SCIENCE AND TECHNOLOGY INSTITUTE
OF THE PHILIPPINES (VIP), APPROPRIATING FUNDS THEREFOR AND FOR
OTHER PURPOSES

Be it enacted by the Senate and House of Representatives of the Philippines in Congress assembled:

CHAPTER I
GENERAL PROVISIONS

1 **Section 1. *Short Title.*** - This Act shall be known as the "Virology Science and
2 Technology Institute of the Philippines (VIP) Act of 2021."

3
4 **Section 2. *Declaration of Policy.*** - It is hereby declared the policy of the State
5 to protect and promote the right to health of every Filipino by ensuring that they are
6 proactively protected from diseases.

7
8 Towards this end, it is also hereby declared the policy of the State to establish a
9 reliable national virology laboratory that shall play a critical role in surveillance,
10 diagnosis and monitoring of viral diseases humans, plants and animals as well as in the
11 understanding of the genetic changes in their viral genome as a prerequisite for a strong
12 public health response to emerging, re-emerging and existing viral diseases in order to

1 raise the level of health of the Filipino and improve their social, economic and cultural
2 conditions.

3
4 It is hereby further declared the policy of the State that a systematic approach
5 to the improvement of our health system requires the establishment of an institution
6 equipped with the necessary capacity, competency, latitude and authority to decisively
7 and scientifically respond to the demands of public health and public health
8 emergencies, crises and situations brought about by viral infections and regulate the
9 operation of other virology laboratories in order to prevent possible public health threats
10 resulting from the operation of these laboratories.

11
12 **Section 3. Definition of terms.** - As used in this Act, the following terms shall
13 mean:

14 (a) *Biosafety* is the application of safety precautions that reduce a laboratory
15 personnel's risk of exposure to a potentially infectious microbe and limit
16 contamination of the work environment and ultimately the community;

17 (b) *Biosafety levels* are divided into four (4). Each level has specific controls for the
18 containment of microbes and biological agents based on internationally-accepted
19 safety standards. The primary risk that determines the levels of containment are
20 infectivity, severity of disease transmissibility and the nature of the work conducted;

21 (c) *Culture medium or growth medium* is a liquid or gel designed to support the growth
22 of microorganisms;

23 (d) *Disinfection* is the process using chemical compounds to exterminate
24 microorganisms but does not necessarily kill all microorganisms especially resistant
25 bacterial spores;

26 (e) *Infectious waste* has been defined to include biological waste, cultures and stocks,
27 pathological waste, and sharps. Each of these categories has a proper disposal
28 method. Infectious wastes must either be incinerated or treated prior to disposal.

29 The following are the infectious wastes:

- 30 i. *Biological waste* includes blood and blood products, excretions, exudates,
31 secretions, suctionings and other body fluids that cannot be directly discarded
32 into the municipal sewer system, but excludes articles contaminated with fully

1 absorbed or dried blood. Biological waste must either be incinerated, sterilized
2 with steam in a dedicated autoclave as described below, or treated by some
3 other nationally recognized method which has been approved and formally
4 adopted by the Department of Environment and Natural Resources (DENR).
5 After treatment, biological waste may be treated as normal refuse.

6 ii. *Cultures and stocks* include etiologic agents and associated biologicals,
7 including specimen cultures and dishes and devices used to transfer, inoculate
8 and mix cultures. The definition also includes wastes from the production of
9 biologicals, serums, and discarded live or attenuated vaccines. Cultures and
10 stocks must be treated in the same way as biological waste.

11 iii. *Pathological waste* includes biopsy materials, all human tissues, and anatomical
12 parts from surgery and other procedures. It also includes carcasses and
13 bedding from animals and plants exposed to pathogens in research, but does
14 not include teeth or preservative agents such as formaldehyde. Pathological
15 waste must be incinerated.

16 iv. *Sharps* includes needles, scalpel blades, lancets, glass tubes that could be
17 broken during handling and syringes that have been removed from their original
18 sterile containers. Sharps must be incinerated.

19 (f) *Kit* or test kit is a commercially packaged system of the principal or key components
20 of an analytical method used to determine the presence of a specific analyte(s) in
21 a given matrix (es). Test kits include directions for their use and are often self-
22 contained, complete analytical systems; but they may require supporting supplies
23 and equipment. The key components frequently represent proprietary elements or
24 reagents that may be readily prepared only by the producer of the kit.

25 (g) *Personal protective equipment* consists of garments placed to protect a laboratory
26 scientist, worker or any other person from getting infected by a viral agent. It
27 consists of standard precautions: gloves, masks and gowns. When working with
28 blood or airborne high infections, it shall also include face protection, goggles and
29 masks or faces shields, gloves or coveralls, head cover and rubber boots;

30 (h) *Reagent* is any natural or synthetic substance used in a chemical or biological
31 reaction in order to produce, identify, or measure another substance;

32 (i) *Risk Group I viruses* are microorganism that is unlikely to cause human, plant or

1 animal disease (e.g. Adeno-associated vims (AAV) types 1-4). These viruses shall
2 be studied in basic virology laboratories;

3 (j) *Risk Group 2 viruses* (moderate individual risk, low community risk) are viral
4 pathogens that can cause human, plant or animal disease but are unlikely to be a
5 serious hazard to laboratory workers, the community, livestock or the environment.
6 Laboratory exposures to these group of viruses may cause serious infection, but
7 effective treatment and preventive measures are available and the risk of spread of
8 infection is limited. Assay systems using these viruses shall be done in biosafety
9 level 2 laboratories. Examples include herpes viruses, foot-and- mouth disease
10 viruses, adenoviruses and unconventional slow viruses;

11 (k) *Risk Group 3 viruses* (high individual risk, low community risk) are viral pathogens
12 that usually cause serious human, plant or animal disease but does not ordinarily
13 spread from one infected individual to another. Effective treatment and preventive
14 measures are available against these group of viruses. Assay systems using these
15 viruses shall be conducted in biosafety level 3 laboratories. Examples include human
16 immunodeficiency vims (HIV), hepatitis B vims (HBV), hantaviruses, Japanese
17 encephalitis vims (JEV), rabies, rift valley fever and yellow fever vims;

18 (l) *Risk Group 4 viruses* (high individual and community risk) are viral pathogens that
19 usually cause serious human, plant or animal disease and that can be readily
20 transmitted from one individual to another, directly or indirectly. Effective treatment
21 and preventive measures are not usually available against these group of viruses.
22 Assay systems using these viruses shall be made in biosafety level 4 laboratories.
23 Examples include Lassa fever, filoviruses, smallpox, Crimean- Congo haemorrhagic
24 fever, avian influenza viruses, Nipah virus, Russian spring-summer encephalitis and
25 Kyasanur forest disease viruses;

26 (m) *Serology* is the scientific study or diagnostic examination of blood serum, especially
27 with regard to the response of the immune system to pathogens or introduced
28 substances;

29 (n) *Smear* is a specimen for microscopic study, the material being spread thinly and
30 unevenly across the slide with a swab or loop, or with the edge of another slide;

31 (o) *Sterilization* is the process of exterminating all microorganisms within or outside an
32 object or material using extreme chemical or physical;

- 1 (p) *Tissue culture* refers to a collection of laboratory techniques and methods in which
2 fragments of a tissue (human, plant or animal tissue) are introduced into a new,
3 artificial environment, where they continue to function or grow; and
4 (q) *Virology* is the study of viruses, vims-like agents including but not limited to their
5 taxonomy, disease-producing properties, cultivation and genetics.
6

7 **CHAPTER II**
8 **VIROLOGY SCIENCE AND TECHNOLOGY**
9 **INSTITUTE OF THE PHILIPPINES**
10

11 **Section 4. *Creation of a Virology Science and Technology Institute of***
12 ***the Philippines (VIP).*** - There is hereby created a Virology Science and Technology
13 Institute of the Philippines (VIP), hereinafter referred to as the Institute.
14

15 The Institute shall be as an attached agency under the Department of Science
16 and Technology (DOST). The DOST, in coordination with the Department of Agriculture
17 (DA) and the Department of Health (DOH), shall promulgate policies for and exercise
18 supervision and control over the Institute.
19

20 **Section 5. *Scope and Coverage of Virology Science and Technology.*** -
21 For purposes of this Act, the scope and coverage of the Institute shall be the extensive,
22 ground-breaking, pioneering and original research projects on the study of viruses for
23 agricultural, industrial, clinical and environmental importance, contagious and non-
24 contagious viral diseases from the standpoint of preventive medicine in humans,
25 animals and plants, improving human, zoological and botanical health and welfare by
26 suppressing infectious and non-infectious viral diseases, and clarifying and supporting
27 the scientific background of viruses in relation to zoological, botanical and human health
28 and medical administration of the government: *Provided,* That the Institute shall be the
29 national reference laboratory for all zoonotic and botanical infections involving viral
30 etiology.
31

32 **Section 6. *The Director of the Institute.*** - The Institute shall be headed by

1 a Director, who shall have a rank of an undersecretary and shall be appointed by the
2 President of the Philippines upon the recommendation of the Advisory Board created
3 under Section 9 of this Act. The Director shall be a qualified virologist possessing a
4 postgraduate degree in virology with three (3) to five (5) years of experience in
5 diagnostic virology.

6
7 The Director shall have overall responsibility for the activities including the
8 supervision of all the staff working in the Institute, and shall be directly responsible for
9 reporting to the Secretary of Science and Technology and the President of the
10 Philippines the results of the various diagnostic assays and research studies performed
11 in the Institute.

12
13 The Director shall be responsible for the implementation of policies and the
14 immediate management of the programs and operations of the Institute including its
15 general institutional affairs, promote research and foster efficient assay and research
16 activities.

17
18 The Director shall be assisted by a Deputy Director, who shall have a rank of an
19 assistant secretary, and shall be appointed by the President of the Philippines upon the
20 recommendation of the Advisory Bouncil.

21
22 **Section 7. Powers and Functions.** - The Institute shall be the principal
23 laboratory of the country in providing quality virology laboratory investigations,
24 researches and technical coordination of the entire network of the virology laboratories
25 in the Philippines.

26
27 The Institute shall perform the following functions:

- 28 (a) Conduct basic and applied research projects on zoological, botanical and human
29 infectious, non-infectious and other intractable diseases of viral etiology with
30 primary focus on their characterization, vector/reservoir transmission, viral ecology,
31 clinical virology, pathogenesis, pathophysiology, and host immune response to
32 these viral pathogens;

- 1 (b) Provide reference services including all that are necessary for ensuring the assay
2 systems for diseases of viral etiology, industrial and technological implications of
3 virology and services involving the storing and supplying pathogenic and non-
4 pathogenic viral agents and their vectors and hosts, standardizing reagents,
5 preparing and supplying reference materials needed for the diagnosis and
6 surveillance of plant, animal and human diseases, educating professional
7 technicians, and information exchange;
- 8 (c) Establish testing, reference and biosafety levels 1,2 3, and 4 research laboratories
9 which are fully compliant with the provisions of this Act and the internationally-
10 accepted guidelines in the establishment and operation of the same;
- 11 (d) Conduct viral disease surveillance program, collection, analysis, and feedback and
12 distribution of information on diseases of viral etiology;
- 13 (e) Comprehensively coordinate the planning and implementation of research projects,
14 approve liaison and coordination with relevant governmental agencies, and
15 coordinate research projects with other research institutions;
- 16 (f) Provide technical advice to national authorities on the progress, needs and
17 aspirations of the virology laboratory network in the country and to regulate the
18 operation of the same;
- 19 (g) Assist national authorities in the planning, organization and supervision of the
20 virology laboratory network;
- 21 (h) Develop technical/training material for use in laboratories in the network to enhance
22 their quality;
- 23 (i) Assess the needs and impart training to the staff of other virology laboratories in
24 the country in quality testing for viral pathogens;
- 25 (j) Validate reagents and kits that may be used nationally;
- 26 (k) Validate new technologies that may become available and recommend their
27 implementation in the country;
- 28 (l) Develop minimum standards, standard operating procedures and research
29 protocols for virology laboratories and assist virology laboratories in their
30 implementation of the same;
- 31 (m) Develop, in consultation with the DOH, DA, other relevant government agencies,
32 the academe, and private enterprises engaged in the industry of virology, a national

- 1 database of viruses and laboratory results;
- 2 (n) Organize external quality assessment schemes to periodically assess the quality of
- 3 testing in networks and suggest remedial measures to those laboratories that show
- 4 poor performance;
- 5 (o) Undertake research to improve the quality and cost-effectiveness of virology
- 6 laboratory services in the country;
- 7 (p) Collaborate with the World Health Organization (WHO) and other international
- 8 agencies in virology researches and technical matters pertaining to improvement of
- 9 laboratories;
- 10 (q) Create within the Institute various divisions that will spearhead basic and applied
- 11 molecular biological research and reference activities in arbovirology, emerging and
- 12 reemerging viral diseases, neurovirology, herpes virology, enteric virology, tumor
- 13 virology, hepatitis virology, acute viral respiratory infections and cytokines, viral
- 14 genomics and molecular genetics and biosafety control studies of viruses, among
- 15 others;
- 16 (r) Promulgate rules and regulations regarding the management and operation of
- 17 virology laboratories in the country as well as its rules of engagement;
- 18 (s) Collect fees in connection with the exercise of its regulatory powers;
- 19 (t) Apply for, receive, and accept bequests, grants, and donation of funds, equipment,
- 20 materials and services needed for the attainment of its objectives;
- 21 (u) Provide grants, research fund, materials and equipment for the conduct of virology
- 22 researches by both public and private higher education institutions;
- 23 (v) Order the suspension or closure of virology laboratories and prosecution of
- 24 individuals and corporations for violations of this Act;
- 25 (w) Establish an editorial office of a refereed journal of virology to published it and a
- 26 library which shall to collect and preserve books, journals and other reference
- 27 materials in the field of virology; and
- 28 (x) Perform such other related activities as may be assigned by the DOST.
- 29

30 **Section 8. *Organization and Personnel.*** - The Institute shall have its

31 technical and administrative support staff as well as consultants as may be necessary.

32 Such consultants may be drawn from the public and private sectors on consultancy or

1 contractual basis and shall be granted honoraria or allowances at such amounts as may
2 be determined in accordance with existing rules and regulations.

3
4 All laboratory workers shall undergo periodic training to increase their laboratory
5 competencies. Attendance to conferences, seminars and trainings shall be given
6 additional service credits.

7
8 **Section 9. *Advisory Board.*** - The Institute shall have an Advisory Board
9 composed of the following officials or their representatives:

10 (a) The Secretary of Science and Technology, Chairman;

11 (b) The Secretary of Health, Co-Chairman;

12 (c) The Secretary of Agriculture, Co-Chairman; and

13 (d) Ten (10) members from the academe who must have distinguished themselves in
14 the field of medical virology, genomics, plant virology, animal virology,
15 epidemiology, genetic engineering and other related disciplines and shall be
16 appointed by the President of the Philippines.

17
18 **Section 10. *Transfer of Biomedical Research Functions.*** - All functions in
19 the Department of Health involving biomedical research in virology and in the
20 Department of Agriculture involving animal and plant virology shall be transferred to
21 the Institute together with their applicable appropriations, records, equipment, property
22 and such personnel as may be necessary.

23
24 Notwithstanding the provisions of this law, the Research Institute for Tropical
25 Medicine shall retain its existing mandate on reference laboratories for public health
26 purposes, as stipulated in relevant laws and rules.

27 28 **CHAPTER III**

29 **VIROLOGY LABORATORY OPERATIONS**

30
31 **Section 11. *Physical structure of virology laboratories.*** - All newly
32 constructed virology laboratories shall be located in separate, multi-storied buildings.

1
2 A virology laboratory shall be situated at the end of a corridor in a building where
3 other laboratories are located in order to restrict entry of visitors, prevent contamination
4 and facilitate maintaining biosafety standards. In cases of existing laboratories, they
5 shall be separated from other areas and facilities that are open to unrestricted staff
6 movement within the building.
7

8 **Section 12. Essential features of a virology laboratory.** - Apart from the
9 biosafety requirements, the following shall be the minimum essential features that must
10 to be incorporated in the design of a virology laboratory:

- 11 (a) Adequate space shall be provided for the safe conduct of laboratory work and for
12 cleaning and maintenance. Designated cubicles, rooms or areas shall be available
13 to carry out different activities, e.g. office rooms, specimen collection cubicle,
14 specimen reception and processing room, serology laboratory, cell culture cubicle,
15 molecular diagnostic laboratory comprising three cubicles, cold room, dark room
16 for fluorescent microscopy, common equipment room, media preparation room,
17 washing and sterilization section, store room, toilets and lunch room;
- 18 (b) Each laboratory room shall have a space for housing a biosafety level 2 cabinet,
19 one workbench, a sink, discard bins, wall cabinets to store consumables, a
20 centrifuge, an incubator and a refrigerator;
- 21 (c) The entire laboratory shall be climate-controlled to maintain a dust-free
22 environment and an ambient temperature of 22-25 °C. Least cell culture cubicles,
23 virus handling cubicles, the serology lab and the molecular biology labs shall also
24 be air conditioned;
- 25 (d) Walls, ceilings and floors shall be smooth, easy to clean, impermeable to liquids
26 and resistant to chemicals and disinfectants normally used in the laboratory. Floors
27 shall be slip- resistant;
- 28 (e) Bench-tops shall be impervious to water and resistant to disinfectants, acids,
29 alkalis, organic solvents and moderate heat;
- 30 (f) Illumination shall be adequate for all activities. Undesirable reflections and glare
31 shall be avoided;
- 32 (g) Laboratory furniture shall be sturdy. Open spaces between and under benches,

- 1 cabinets and equipment shall be accessible to cleaning;
- 2 (h) Storage space shall be adequate to hold supplies for immediate use and thus
3 prevent clutter on bench tops and in aisles. Additional long-term storage space
4 conveniently located within or outside the laboratory area shall also be provided;
- 5 (i) All doors shall have vision panels, appropriate fire ratings and self-closing;
- 6 (j) Facilities for storing outer garments, personal items, pantry and restrooms shall
7 be provided outside the laboratory working area;
- 8 (k) Hand-washing basins with running tap water shall be provided in each laboratory
9 room, preferably near the exit door. A dependable supply of good quality water
10 shall essential. There must be no cross-connections between sources of laboratory
11 water supply and drinking water supplies;
- 12 (l) There shall be reliable and adequate electricity supply and emergency lighting for
13 safe exits. A stand-by generator shall be available at least for some equipment
14 such as incubators, biosafety cabinets, freezers etc.; and
- 15 (m) Safety systems shall cover fire, electrical emergencies, emergency shower and
16 eyewash facilities including systems for avoiding overcrowding and too much
17 equipment, pest control and prevention particularly rodents and arthropods and
18 prevention of unauthorized entry into the laboratory areas.

19
20 **Section 13. *Equipment and supplies.*** - The virology laboratory shall have
21 adequate equipment which shall take into account certain general principles, including:

- 22 (a) The equipment, facilities and supplies must be designed to prevent or limit contact
23 between the operator and the infectious material (e.g. biosafety cabinets, electronic
24 pipetting aids, etc.);
- 25 (b) The equipment and facilities must be made of materials that are impermeable to
26 liquids, resistant to corrosion and meet internationally-accepted structural
27 requirements;
- 28 (c) The equipment and facilities must be free of sharp edges, burrs and unguarded
29 moving parts;
- 30 (d) The equipment and facilities must be designed, constructed and installed to facilitate
31 simple operation and provide for ease of maintenance, cleaning, decontamination
32 and certification testing; and

- 1 (e) Glasswares and other breakable materials must be avoided wherever possible.
2 Essential and desirable equipment required for a virology laboratory must conform
3 with standards set by the Institute and internationally-recognized manuals and
4 guidelines for virology laboratory operations.
5

6 **Section 14. Biosafety requirements of laboratories.** - The biosafety
7 Infrastructure shall be designed on the basis of risk assessment for handling specific
8 pathogens. The desired biosafety levels shall be established on the basis of professional
9 judgement based on risk assessment and on internationally-accepted guidelines on the
10 handling and management of specific viral agents.

- 11 (a) In addition to the minimum essential features stipulated in Section 12, a biosafety
12 level 2 laboratory shall have the following minimum requirements:

- 13 1. Inward airflow ventilation or controlled ventilating system;
- 14 2. On-site Autoclave; and
- 15 3. Biological safety cabinets.

- 16 (b) In addition to the minimum essential features stipulated in Section 12, biosafety
17 level 3 and 4 laboratories shall have the following minimum requirements:

- 18 1. Isolation of laboratory;
- 19 2. Room sealable for decontamination;
- 20 3. Inward airflow ventilation, controlled ventilating system and HEPA-filtered;
- 21 4. Double-door entry;
- 22 5. Airlock;
- 23 6. Airlock with shower;
- 24 7. Anteroom;
- 25 8. Anteroom with shower;
- 26 9. Effluent treatment;
- 27 10. On site, in-laboratory and double-ended Autoclave;
- 28 11. Biological safety cabinets; and
- 29 12. Personal safety monitoring capability.

- 30 (c) Biosafety level 3 and 4 laboratories must be separated from general traffic flow and
31 accessed through an anteroom (with double door entry or basic laboratory - Biosafety
32 Level 2) or an airlock.

- 33 (d) An autoclave must be available within the facility for decontamination of wastes prior to

1 disposal.

2 (e) A sink with hands-free operation must available.

3 (f) Inward directional airflow must be established and all work with infectious materials
4 must conducted within a biological safety cabinet.

5
6 **Section 15. *Handling of viruses and specimens containing viruses.* -**

7 Unless the recommended biosafety level facilities are available, the laboratory should
8 not handle a particular virus. In situations where there is an outbreak of a viral illness
9 and the required biosafety levels are not available, the specimen shall be collected and
10 referred to the nearest laboratory that has the required biosafety laboratory. Specimens
11 collected from patients who are suspected of suffering from viral infections caused by
12 agents under risk groups 3 or 4 shall be directly forwarded to the reference laboratory
13 or the Institute which has the required facilities for the handling such agents.

14
15 **Section 16. *Minimum staff requirement for a virology laboratory.* -** The
16 minimum staff requirements for a virology laboratory shall include:

17 (a) A qualified virologist possessing a postgraduate qualification in virology
18 with three years of experience in diagnostic virology shall be the chief of the laboratory.
19 He shall have overall responsibility for the activities of the laboratory and shall supervise
20 all the staff working in it. In addition, he shall be directly responsible for reporting results
21 of the various diagnostic assays performed in the laboratory;

22 (b) Two junior microbiologists possessing a master's degree in medical, animal
23 or plant microbiology with one to two years of experience in diagnostic virology. These
24 microbiologists shall be responsible for the day-to-day operation of the laboratory
25 including the supervision of technical staff who carry out the various diagnostic tests,
26 stock management and procurement of laboratory supplies and diagnostic kits, quality
27 control and quality assurance;

28 (c) Two laboratory technologists possessing a bachelor's degree in medical
29 technology, one to be trained in cell culture and virus isolation methods and the other
30 to be trained in serology. The technicians shall be responsible for specimen processing,
31 testing, laboratory safety, maintenance of laboratory records and media preparation;
32 and

33 (d) One or two laboratory supportive staff.

- 1 (e) The duties and responsibilities of all the staff shall be clearly outlined and they shall
2 be provided with periodic training to upgrade the knowledge and skills of the
3 laboratory operation and management to ensure that the laboratory is abreast with
4 contemporary diagnostic methodology as well as maintain quality in the services
5 rendered.

6
7 **Section 17. *Use of personal protective equipment in virology***
8 ***laboratories.*** - Specially designed coveralls which afford protection up to the neck,
9 facemasks or frill face respirators and gloves shall be used at all times in the virology
10 laboratory. Additional personal protective equipment shall be used when handling highly
11 pathogenic viruses.

12
13 **Section 18. *Amenities.*** - Hand basins must be provided in each laboratory.
14 Lockers for staff clothing must be available outside but near the laboratory rooms.
15 Pantry/rooms for eating and drinking must be provided close to laboratory rooms.

16
17 **Section 19. *Health of staff.*** - Pre-employment medical examination for all staff
18 shall be made. Medical monitoring for workers in biosafety level 3 and 4 laboratories
19 shall also be conducted regularly. The scope of the monitoring shall depend on the agent
20 being handled. Women who work with viruses must disclose their pregnancy as soon as
21 possible. Individual evaluation of the risks involved in continued employment in the
22 virology laboratory must also be done.

23
24 **Section 20. *Medical surveillance.*** - A system that records and follows up all
25 cases of illness among laboratory staff to ascertain the source of infection and initiate
26 any follow-up action shall be developed.

27
28 **Section 21. *Accidents.*** -

- 29 (a) All accidents causing personal injury with or without exposure to infectious agents
30 shall be reported to the supervisor or safety officer. Records should be kept of all
31 staff sicknesses, injuries and accidents, and of x-rays and immunization;
32 (b) A qualified first-aid provider must be present at all times in the laboratory. He/she
33 must receive additional training in dealing with exposure to and ingestion of

- 1 infectious, toxic and corrosive chemicals;
- 2 (c) A well sign-posted standard first aid kit for minor injuries must be in a conspicuous
- 3 location inside the laboratory; and
- 4 (d) Standard operating procedures for management of post-exposure prophylaxis
- 5 must be in place.

6

7 CHAPTER IV

8 LABORATORY WASTE MANAGEMENT

9

10 **Section 22. *Management of laboratory waste.*** - Laboratory waste shall be

11 segregated into color-coded containers corresponding those for incineration, for

12 autoclaving, normal household waste and for soiled linens.

13

14 The following practical methods shall be used in treating contaminated laboratory

15 waste:

- 16 (a) Sterilization by autoclaving using timed exposure of materials to steam above
- 17 atmospheric pressure at temperatures above 100°C.
- 18 (b) Chemical disinfection which is regarded as the first line defense, especially in the
- 19 case of discarded bench equipment, and which should be followed by autoclaving
- 20 or incineration. Chemical disinfection shall use clear sodium hypochlorite, clear
- 21 phenolics, alcohols and aldehydes.
- 22 (c) Incineration involves the transport of waste materials off-site for disposal using an
- 23 incinerator.
- 24 (d) Other internationally-accepted forms of disinfection and decontamination shall be
- 25 employed in effectively preventing accidents and contamination.

26

27 **Section 23. *Infectious waste.*** - Infectious wastes shall be segregated from

28 general wastes as they need to be autoclaved or incinerated before being removed from

29 the area in which they are generated.

30

31 **Section 24. *Routine contaminated wastes.*** - Laboratory workers shall take

32 care to segregate their wastes from general wastes. General wastes shall be

33 decontaminated prior to removal from the area in which they are generated.

1 Internationally-accepted alternative means of decontamination to autoclaving or
2 incineration may be used, provided they are effective.

3
4 **Section 25. *Management of sharps.*** - All sharps shall be segregated from
5 other wastes and placed in dedicated and labelled single-use rigid containers
6 immediately after use. Sharps containers shall not be compacted or emptied into
7 ordinary waste streams.

8
9 **Section 26. *Labelling of wastes.*** -

10 (a) All wastes shall be identified with an appropriate type of label which shall remain
11 attached to the waste. The label shall state the nature of waste material, the
12 department, date, and the name of the person responsible for the waste.

13 (b) In transporting wastes through buildings and across campus, the main consideration
14 shall be the non-exposure of anyone to the risks from the contaminated material.
15 Containers shall be leak-proof.

16 (c) Wastes shall be decontaminated as far as is practical before removal from the area
17 of generation. All laboratories shall have access to local autoclave and other
18 appropriate decontamination facilities so as to minimize the need to transport
19 contaminated wastes around laboratories.

20
21 **CHAPTER V**

22 **QUALITY SYSTEMS IN VIROLOGY LABORATORIES**

23
24 **Section 27. *Quality systems.*** - A quality system shall be instituted in all
25 virology laboratories. It shall be comprehensive and shall cover all aspects from the
26 decision to collect the specimen to the interpretation of results. Systematic efforts
27 through organizational structure and efficient utilization of resources shall be used
28 to implement all the steps that shall assure generation of quality reports by the laboratory.
29 It shall aim at consistency, reproducibility, traceability and efficaciousness of the
30 laboratory services.

31
32 **Section 28. *Documentation.*** - Routine procedures shall be described in written
33 Standard Operating Procedures (SOPs). They shall be reviewed regularly and modified,

1 If necessary. The modified versions shall be signed and dated by the laboratory director.
2 The most recent version of SOPs shall be available directly at the work place. The old
3 versions shall be kept in the laboratory and shall be archived if required. The records
4 shall be stored for long periods of time but shall be available for prompt retrieval. Safe
5 archiving of all records shall be ensured.

6
7 Archiving of the source documents and other essential documents shall be done in such
8 a way that data are kept in an integer state and can neither be lost nor altered to achieve
9 this goal. Records of usage, maintenance and calibration shall be kept in the laboratory
10 and shall be routinely monitored. Reports of the tests shall be released only after proper
11 scrutiny and documentation of the scrutiny with the signature and date by the laboratory
12 supervisor.

13
14 **Section 29. *Standard operating procedure (SOP).*** - SOP is one of the most
15 important documents in a diagnostic laboratory. Apart from providing the complete
16 details of how exactly a test or a procedure is carried out in a laboratory, the SOP shall
17 provide information on specimen collection, laboratory safety instructions, purpose and
18 limitations of the procedure, turnaround times, interpretation of results, and above all,
19 the line of authority. The procedure manual used in the laboratory shall be complete
20 enough in detail in order that any laboratory scientist can perform the procedure without
21 additional information. One copy of the manual shall be readily available to bench
22 personnel, and another copy shall be stored separately in case of accidents. A document
23 control system shall be instituted to ensure that up-to-date document are used.

24
25 **Section 30. *Quality control checks areas.*** - The following, among others,
26 shall be the minimum critical quality control check areas:

- 27 (a) *Specimen transport.* Viral specimens held for short periods shall be refrigerated,
28 while those for longer periods shall be frozen at -20°C or -70°C;
29 (b) *Transport media.* The composition and type of viral transport media can affect viral
30 isolation rates. Culture media shall be a balanced isotonic solution at physiological
31 pH. It shall contain a substance that will stabilize the virus such as gelatin, fetal calf
32 serum or bovine serum albumin, and antibiotics against bacteria and fungi. The
33 swab shall be made of a material that is non-toxic to viruses;

- 1 (c) *Smears*. Smears must contain a reasonable number of cells, be of a reasonable
2 size, and not mixed with blood or pus in order to avoid non-specific staining;
- 3 (d) *Specimens for serology*. Excessively haemolyzed, lipaemic, bacterially-
4 contaminated, or leaking specimens shall be rejected. Sera shall be heat-
5 inactivated depending on the tests to be performed. In the event of a specimen
6 being rejected, the sender shall be informed, preferably by an oral report followed
7 by a written one. Extenuating circumstances may warrant the acceptance of a
8 substandard specimen;
- 9 (e) *Tissue culture and media*. Within a given cell line, there may be significant
10 variations in sensitivity to virus isolation which may depend on the particular cell
11 line or clone and the passage number. Information on a particular cell line shall be
12 recorded accurately including the source, type, passage number, confluency and
13 cell condition. These back-up systems shall include freezing and storage of low
14 passage cells at -70°C liquid nitrogen tanks, use of paired stock flasks or carrying
15 of a parallel set of stock flasks using a separate set of tissue culture reagents and
16 glassware;
- 17 Other quality control procedures that may aid in minimizing the risk of
18 contamination shall include the exclusion of laboratory with infectious diseases
19 from handling tissue culture, and separate laboratory apparel, reagents and
20 glassware for tissue culture. Cell lines shall be handled separately and the cabinet
21 shall be decontaminated in between uses;
- 22 (f) *Media*. Following filter sterilization, aliquots of the media shall be taken and
23 checked for bacteriological or fungal contamination. These samples shall be
24 examined daily for five days and must be free from contamination. Aliquots of all
25 other medium components such as fetal calf serum and L-glutamine shall also be
26 checked. New lots of medium and fetal calf serum that have passed the sterility
27 check shall be monitored for their ability to support cell growth;
- 28 (g) *Reagents and kits*. Reagents and kits shall only be ordered from reputable
29 manufacturers and dealers with reliable transportation systems. Upon receipt, the
30 reagents shall be checked for obvious breakage or contamination. The quantity,
31 source, lot number and date of receipt shall be entered in a logbook and the
32 reagents stored according to the manufacturer's storage specifications. When new

lots of any reagent are opened, the date shall be noted on the container. Caution shall be exercised in the case of kits as different components of a kit may require different storage conditions and have different expiration dates; and

(h) *Instruments.* Laboratory instruments shall be subjected to routine preventive maintenance and checked and calibrated on a regular basis. Some of these checks may be performed by laboratory staff and entered into a logbook. The following shall be the minimum routine laboratory maintenance and performance checks on instruments:

- i. *Incubators:* daily temperature, CO₂ and humidity checks. Weekly decontamination of interior;
- ii. *Safety cabinets:* daily air pressure check and cleaning of UV lamp. Work surface should be decontaminated after each use. Annual checks for air velocity and filter integrity and paraaldehyde decontamination, as applicable;
- iii. *Microscopes:* daily cleaning of objectives and stage, log of lamp usage and annual overhaul. Refrigerators and freezers: daily temperature check; annual check of compressor and refrigerant levels;
- iv. *Water baths:* daily temperature checks, weekly decontamination;
- v. *Refrigerated centrifuges:* weekly decontamination, annual inspection of motor, speed calibration and drive system;
- vi. *Autoclaves:* daily temperature check and monthly spore strip testing;
- vii. *pH meters:* single reference buffer check before each use, multiple point check monthly; and
- viii. *Pipetting devices:* gravimetric volume check monthly; annual overhaul.

Section 31. Continuing professional education. - All virology laboratories shall regularly provide local and international education and training to its laboratory workers at the expense of the laboratory.

Section 32. Incentives of laboratory workers. - The DOST shall device a scheme which shall provide incentives to laboratory workers in virology laboratories whose outputs result in high-impact medical, agricultural, technological and industrial

1 innovations.

2
3 **Section 33. Assessment of Quality System.** - The quality system shall be
4 assessed either through an onsite inspection (audit) or by sending known but
5 undisclosed material to the laboratories for testing (quality assessment scheme). The
6 latter can be done within the Institute by internal staff (internal quality assessment
7 scheme - IQAS) or through an external agency (external quality assessment scheme
8 - EQAS).

9 **CHAPTER VI**
10 **PENALTY PROVISIONS**

11
12 **Section 34. Penalties. -**

13 (a) In addition to acts or omissions already penalized by existing laws, the following
14 faults or omissions shall be punishable by imprisonment of at least 12 years and 1
15 day to 20 years (*reclusion temporal*) or a fine of not less than five hundred thousand
16 pesos (P500,000.00) but not more than five million pesos (P5,000,000.00), or both,
17 such imprisonment and fine, at the discretion of the court:

- 18 i. Any person who introduces high-risk viral pathogens into the domestic
19 environment without obtaining a permit, in violation Section 15 of this
20 Act.
21 ii. Any person who refuses, interferes with, or evades an inspection for the
22 safety control of high-risk viral pathogens;
23 iii. Any person who neglects to apply for permit for the operation of the
24 virology laboratory;
25 iv. Any person who makes a false statement, presents false materials or
26 documents, or intentionally omits or conceals any fact, in violation of any
27 of the provision of this Act;

28 (b) In addition to acts or omissions already penalized by existing laws, the following
29 faults or omissions shall be punishable by imprisonment of at least 6 years and 1
30 day to 12 years (*prision mayor*) or a fine of not less than one hundred thousand
31 pesos (P100,000.00) but not more than one million pesos (P1,000,000.00), or both,
32 such imprisonment and fine, at the discretion of the court:

1 i. Any person who operates a virology laboratory in violation of Sections 11,
2 12, 13 and 14 of this Act.

3 ii. Any person who disposes laboratory waste in violation of Sections 22, 23,
4 24, 25 and 26 of this Act;

5 (c) In addition to acts or omissions already penalized by existing laws, the following
6 faults or omissions shall be punishable by imprisonment of at least 6 months and
7 1 day to 6 years (*prision correctional*) or a fine of not less than one hundred
8 thousand pesos (PI 00,000.00) but not more than five hundred thousand pesos
9 (P500,000.00), or both, such Imprisonment and fine, at the discretion of the court:

10 i. Any person who operates a virology laboratory in violation of Sections
11 16, 17, 18, 19, 20 and 21 of this Act.

12 ii. Any person who operates a virology laboratory in violation of Sections
13 27, 28, 29, 30, 31, 32 and 33 of this Act;
14

15 **Section 35. Joint Penalty.** - Where a representative of a corporation, or an
16 agent or an employee of, or any other person employed by, a corporation or individual
17 commits any violation of the provisions of this Act in connection with the business of
18 the corporation or individual, in addition to the punishment of such violator, the
19 corporation or individual shall be punished by a fine under the respective provisions of
20 Section 34.
21

22 **Section 36. Administrative Penalty.** - In addition to acts or omissions
23 already penalized by existing laws, the any government official or employee who, by
24 fault or omission, violates any provision of this Act shall be perpetually disqualified
25 from holding public office with forfeiture of benefits in favor of the State.
26

27 **CHAPTER VII**

28 **OTHER PROVISIONS**

29

30 **Section 37. Congressional Overnight Committee on the Virology**
31 **Science and Technology Institute of the Philippines.**— To monitor the
32 implementation of this Act, there shall be a Congressional Oversight Committee on the

1 Virology Science and Technology Institute of the Philippines, composed of the Chair
2 and four (4) members of the House Committee on Science and Technology, Chair of
3 the House Committees on Health and Agriculture and Food and the Chair and four (4)
4 members of the Senate Committee on Science and Technology, and the Chair of the
5 Committees on Health and Demography and Agriculture, Food and Agrarian Reform.
6 No part of this Act shall be construed as to limit the oversight powers inherently or
7 actually possessed by the same committees.
8

9 **Section 38. *Staffing.*** —The Secretary of Science and Technology, in
10 consultation with the Department of Budget and Management (DBM), shall determine
11 the organizational structures, qualification standards, staffing pattern and
12 compensation of the newly created Institute and other positions which are established
13 under this Act in accordance with existing laws, rules and regulations.
14

15 **Section 39. *Appropriations.*** - The amount needed for the initial
16 implementation of this Act shall be taken from the current year's appropriations of the
17 DOST. Thereafter, such sums, as may be necessary for its continued implementation,
18 shall be included in the annual General Appropriations Act.
19

20 **Section 40. *Implementing Rules and Regulations.*** - The Secretary of
21 Science and Technology shall promulgate the necessary rules and regulations within
22 ninety (90) working days from the effectivity of this Act.
23

24 **Section 41. *Separability Clause.*** — If any portion or provision of this Act is
25 subsequently declared invalid or unconstitutional, other provisions hereof which are
26 not affected thereby shall remain in full force and effect.
27

28 **Section 42. *Repealing Clause.*** — All other laws, acts, presidential decrees,
29 executive orders, presidential proclamations, issuances, rules and regulations, or parts
30 thereof which are contrary to or inconsistent with any of the provisions of this Act are
31 hereby repealed, amended, or modified accordingly.
32

1 **Section 43. *Effectivity.*** — This Act shall take effect fifteen (15) days after its
2 publication in the Official Gazette or in a newspaper of general circulation.

Approved,